Portfolio companies news

14 December 2016

Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

Сlearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NBI will become effective at market open on  Monday, December 19, 2016 .

09 December 2016

Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock

Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of  $75 million  of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional  $11.25 million  of shares of common stock at the public offering price, less the underwriting discount.

07 December 2016

Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock

Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of  $75 million  of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional  $11.25 million  of shares of common stock at the public offering price, less the underwriting discount.

16 November 2016

Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC).  In addition to profiling genome wide copy number variation (CNV) from single cells, the authors also validated the ability to characterize the extent of genomic instability within individual CTCs.

15 November 2016

Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing that the combination of its CNS-selective GABA_A modulator ganaxolone and diazepam administered intravenously (IV) produced a synergistic effect in blocking pilocarpine-induced seizures in a benzodiazepine refractory model of status epilepticus (SE). 

15 November 2016

Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 1/2 clinical trial (the “HULK” trial) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of diabetic macular edema (“DME”).

10 November 2016

Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the third quarter ended September 30, 2016. In addition, the Company provided a pipeline update as well as a review of upcoming milestones. As of September 30, 2016, Syndax had $115.6 million in cash, cash equivalents and short-term investments.

10 November 2016

ReVision Optics Raises $32 Million to Fund Expansion of U.S. Commercialization of Raindrop® Near Vision Inlay

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that it has raised $32 million in an equity financing that was led by JJDC, with pro rata participation or better by current investors Canaan Partners, Domain Associates, InterWest Partners and ProQuest Investments.

10 November 2016

Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results

Neothetics, Inc.  (NASDAQ:NEOT) today provided a business update on its strategic initiatives and reported financial results for the third quarter 2016.

09 November 2016

Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter ended  September 30, 2016  and provided an update on its development programs.